{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/65337aeb32aab9001268a81f/65a2acc62e84290016bf9109?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"The PACER trial","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/65337aeb32aab9001268a81f/1705159840942-e4c615a82a609091e3056d13ad8ba771.jpeg?height=200","description":"<p>In this, the first episode Drs Pip Nicolson and Rich Buka take a deep dive into the PACER trial: Platelet Transfusion before CVC Placement in Patients with Thrombocytopenia. After a quick round up of other trials that have sparked their interest, Pip and Rich discuss about the study aims and outcomes, before interviewing Dr Floor van Baarle, lead study author before discussing the clinical implications of the trial with Prof Simon Stanworth.</p><p><br></p><p>Follow Pip, Rich, and HaemSTAR on X/Twitter: <a href=\"http://www.twitter.com/PipNicolson\" rel=\"noopener noreferrer\" target=\"_blank\">@PipNicolson</a>, <a href=\"http://www.twitter.com/RichardBuka\" rel=\"noopener noreferrer\" target=\"_blank\">@RichardBuka</a>, and <a href=\"http://www.twitter.com/HaemSTAR_UK\" rel=\"noopener noreferrer\" target=\"_blank\">@HaemSTAR_UK</a></p><p><br></p><p>To claim CPD credits, please email <a href=\"mailto:haemstarnetwork@gmail.com\" rel=\"noopener noreferrer\" target=\"_blank\">haemstarnetwork@gmail.com</a>.</p><p><br></p><p><strong>Links</strong></p><p><br></p><ul><li><a href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa2214322\" rel=\"noopener noreferrer\" target=\"_blank\">van Baarle et al. Platelet Transfusion before CVC Placement in Patients with Thrombocytopenia. NEJM, 2023</a>.</li><li><a href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa2216455\" rel=\"noopener noreferrer\" target=\"_blank\">Matsushita et al. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors (explorer7). NEJM, 2023.</a></li><li><a href=\"https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.066485\" rel=\"noopener noreferrer\" target=\"_blank\">Joosten et al. Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. Circulation, 2023.</a></li><li><a href=\"https://www.nejm.org/doi/full/10.1056/NEJMc2307721\" rel=\"noopener noreferrer\" target=\"_blank\">Warkentin et al. Adenovirus-Associated Thrombocytopenia, Thrombosis, and VITT-like Antibodies. NEJM, 2023</a></li><li><a href=\"https://jamanetwork.com/journals/jama/article-abstract/2809417\" rel=\"noopener noreferrer\" target=\"_blank\">Zhao et al. Intracerebral Hemorrhage Among Blood Donors and Their Transfusion Recipients. JAMA, 2023</a></li></ul><p><br></p><p><strong>HaemSTAR </strong>is an independent UK-wide network of registrars in clinical haematology, interested in promoting and performing research in classical haematology. Our focus is on collaborative projects across haemostasis &amp; thrombosis, transfusion, general haematology, and obstetric haematology.</p><p><br></p><p>This episode was sponsored by Sobi as a hands-off educational grant. Sobi had no editorial input whatsoever.</p><p><br></p><p><em>Produced by Joe Apperley. All rights reserved.</em></p>","author_name":"Richard Buka"}